MELBOURNE, AUSTRALIA: Telix Pharmaceuticals Limited, an Australian company that develops radiopharmaceuticals for cancer diagnosis and treatment, has announced its intention to acquire QSAM Biosciences, Inc., a U.S. based clinical stage company that is developing a novel therapy for bone cancer. QSAM’s lead asset, CycloSam®, is a radioactive compound that selectively targets and kills cancer cells…